Status
Conditions
Treatments
About
Gynecomastia is defined as a benign enlargement of the mammary glands, commonly diffused among men. The prevalence of gynecomastia ranges from 38 to 64 percent in the male population.
Gynecomastia can affect normal self-esteem and sexual identity and often patients feel ashamed of their bodies during normal social activities.
The surgical management of the high-grade gynecomastia Simon's grade III or Rohrich's grade IV has remained problematic because both liposuction and conventional subcutaneous mastectomy without skin excision have frequently resulted in significant residual skin redundancy, requiring a second operation for skin resection.
Two Classification Systems of Gynecomastia
Rohrich's Classification I, Minimal breast hypertrophy without ptosis; hypertrophy is either primarily glandular or fibrous II, Moderate breast hypertrophy without ptosis; hypertrophy is either primarily glandular or fibrous III, Severe breast hypertrophy with grade I ptosis glandular or fibrous IV, Severe breast hypertrophy with grade II or III ptosis glandular or fibrous Simon's Classification I, Minor breast enlargement without skin redundancy. IIa, Moderate breast enlargement without skin redundancy IIb, Moderate breast enlargement with minor skin redundancy III, Gross breast enlargement with skin redundancy that simulates a pendulous female breast Smoot stated that this approach for high-grade gynecomastia has several disadvantages. There are difficulties in obtaining precertification from third-party payers for a second operation for skin resection. In addition, the adolescent patient is often very anxious during the ensuring 1 year after the original mastectomy when skin excess is quite apparent and awaiting spontaneous shrinkage.
Currently, there are 4 main different approaches for the management of high-grade gynecomastia:
First is simple mastectomy, which is done with free nipple graft accepting the long transverse scar and the grafted appearance of the nipple areola complex. Second is a modification of breast reduction is done with nipple transposition on a single dermal pedicle or vertical bipedicle. A visible chest scar is also present, but the blood supply of the nipple-areola complex is preserved.
Third is ultrasound assisted liposuction is performed first and after several months, accept that several patients will require a second operation to excise the significant residual skin redundancy. Fourth is a single-stage procedure is done in which sub cutaneous mastectomy and circumareolar skin excision are performed. The purse string skin closure limits the scar to the circumareolar area.
Open excision techniques base their principle on a direct view and management of the gland, through several types of surgical accesses according to the surgeon's preference and entity of the defect. The main advantage of open excision is the direct control of the hemostasis and redundant skin control, with the main disadvantage of permanent scars, whose quality cannot be predicted.
Only Gusenoff et al have proposed a classification with corresponding operative treatment options, whose grades taken into account the laxity of the breast skin and the upper abdomen, the location of the inframammary fold IMF, and the lateral fat role.
Minimal excess skin and fat, minimal alteration of NAC, normal IMF, No lateral skin roll: a Minimal excess skin and fat, minimal alteration of NAC, normal IMF, lateral skin roll: b NAC and IMF below, the ideal IMF, lateral chest roll, minimal upper abdominal laxity: c NAC and IMF below the ideal IMF, lateral chest roll, significant upper abdominal laxity: d
Full description
Cases will be divided into 3 groups according to skin incision:
Group A: circumerolar skin excision Group B: elliptical skin excision with pedicled flap +_ lateral roll excision. Group C: elliptical skin excision with free nipple areola complex +_ lateral roll excision.
Markings
-The preoperative drawings proceed with the patient in standing position.
Group A:
Group B:
The sternal notch with the mid sternal line, the inframammary crease line and the mid breast line.
The new nipple position is located on the 4th intercostal space MCL.
The mid breast line is marked from the clavicle to the nipple and then continued from the inframammary crease down the lower thoracic wall.
the new inframammary fold is in the 6th intercostal space about 2-3 cm beneath the ideal NAC position.
Within this marking the inferior pedicle is designed starting from the NAC apex down to the actual inferior mammary fold. The base of the inferior pedicle should not measure less than 6cm.
The excised part marked as an elliptical excision between the actual and ideal inframammary fold with extension to the lateral roll if present.
The symmetry of the markings, especially the new NAC positions, are checked in front of a mirror.
Group C:
Surgical procedure:
GROUP A:
GROUP B:
GROUP C:
Postoperative Care
Post-operative data:
Breast measurements: the same measurements that were taken preoperatively. patient satisfaction level: which is measured using a questionnaire that have scored through points: completely dissatisfied, slightly dissatisfied, poorly satisfied, fairly satisfied, completely satisfied. aesthetic outcome, nipple sensation , nipple color ,scar satisfaction and muscular contour.
Nipple assessment : colour ,sensitivity and vascularity Scar assessment by VANCOUVER SCAR SCALE 6 months postoperative complication: early such as wound dehiscence, ischemia, hematoma and seroma. Late complications such as nipple pigmentation, nipple sensation, scar, aesthetic outcome.
Photographic Documentation: At the same positions taken preoperatively.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
1- Age is below 18 years and above 60 years. 2- Grade I and IIA gynecomastia according to Simon classification. 3- Psychological problems. 4- Non compliant patient. 5- Unstable weight in last 6 months
Primary purpose
Allocation
Interventional model
Masking
45 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal